Innovating Novel Combination Therapies & Maximising Preclinical & Clinical Development to Improve Glioblastoma Targeting & Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need
Glioblastoma remains one of the most aggressive and devastating cancers, leaving patients and families with limited options and urgent need for progress. Yet, the treatment landscape is beginning to shift, projected to grow significantly by 2034 as science-driven approaches and novel therapies gain momentum. Merck’s landmark acquisition of Modifi Bio is more than a business milestone, it’s a signal of renewed hope in a field that has long faced barriers to investment and breakthroughs.
As we look toward 2026, sustaining this progress is not just important, it’s critical for the patients who cannot wait. The 7th Glioblastoma Drug Development Summit is your opportunity to accelerate innovation and bring life-changing therapies closer to those who need them most.
Over three transformative days, with six deep-dive workshops and 90+ leading experts from biotech, pharma, and investment, we will unite around one shared mission: to change the future for glioblastoma patients.
Together, we’ll explore:
- Innovating combination strategies to overcome resistance and improve outcomes for patients
- Building robust preclinical and clinical frameworks that shorten the path from lab to bedside
- Mobilizing investment and collaboration to deliver promising therapies faster
- Harnessing AI’s power to unlock new insights and accelerate research
Join leading organizations, including Laminar Pharma, Medicenna, Merck, AstraZeneca, CNS Pharmaceuticals, Imvax, Tactical Therapeutics, and many more, as we turn scientific ambition into patient impact.
Every breakthrough represents more than scientific progress, it signifies hope for patients, families, and communities affected by glioblastoma. Together, we have the opportunity to transform the standard of care and deliver meaningful advances where they are most urgently needed.
Attending Companies Include
The diverse content that covered everything from funding GBM trials to new technologies/approaches to early clinical solutions. The round tables were a good way to promote discussion.
Chief Business Officer, Global Coalition for Adaptive Research
I was extremely pleased with the way the entire summit was organized. Everything from the line up of the speakers to the networking opportunities was very well planned and executed.
VP, Research & Development, Diakonos Oncology
The summit covered diverse important topics in GBM field, ranging from more basic to clinical and investment. Great opportunities for discussion on key open topics to understand perspective from leaders in their area of focus.
CEO, Medicenna Therapeutics
Explore the Full Event Guide
- 90+ industry attendees
- 25+ World Class Speaker
- 6 deep-dive workshops, covering end-to-end drug development
- 8+ Hours on Networking
- The world’s only industry-led forum focussed on Glioblastoma drug development
Investor & Partnership Panel:
Despite the urgent unmet need, investment in glioblastoma therapeutics remains constrained by scientific complexity, regulatory uncertainty, and limited commercial upside, making it one of the most underfunded yet high-impact opportunities in neuro-oncology.
In response to this, we have compiled a high-profile group of investors and search and evaluation executives, ready to share their insights, priorities, and advice for biotech looking to secure that all-important funding.
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.